Trastuzumab(Herceptin®) Immunogenicity ELISA
€780.00
In stock
SKU
EL-141-201
INTRODUCTION
Trastuzumab (Herceptin® ) is a humanized recombinant monoclonal antibody used for the treatment of primary breast cancers overexpressing human epidermal growth factor 2 (HER2). Repeated dosing of Trastuzumab has been reported to induce a neutralizing antibody response resulting in reduce efficacy of Trastuzumab. This kit allows researchers to qualitatively monitor the presence of anti-Trastuzumab antibodies in biological matrices.
PRINCIPLE OF THE ASSAY
This immunogenicity assay employs the bridging ELISA technique. Capture antibody is precoated onto a 96 well microplate. Quality control and test samples are pipetted into the appropriate wells. Anti- Trastuzumab present in biological matrices is bound by the immobilized capture antibody. After washing away any unbound substances, secondary antibody is added to the wells and after a final wash a detection reagent is added. The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development.
The color development is proportional to the amount of anti-Trastuzumab present in test samples. Three levels of QC samples give a qualitative reference signal which can be used to determine the level of anti-Trastuzumab antibody in the unknown samples. The color development is stopped and the intensity of the color is measured.
Product Properties
Detection method: Peroxidase / OD450
Storage and stability: Stable at -20°C for 1 year
Safety Warnings and Precautions: Research Use Only. Follow instructions.
Precision : Intra-assay coefficient of variation (CV) <10%. Inter-assay CV <10%.
Detection limit : 31.3ng/ml
Each kit includes:
- Coated microtiter plate, 96 wells
- QC samples - 4x50ul
- 10X wash buffer - 25ml
- Assay buffer - 50ml
- 1000X secondary antibody - 17ul
- 1000X detection reagent - 17ul
- TMB - 12ml
- TMB stop solution - 12ml
- Plate sealers - 3
Trastuzumab (Herceptin® ) is a humanized recombinant monoclonal antibody used for the treatment of primary breast cancers overexpressing human epidermal growth factor 2 (HER2). Repeated dosing of Trastuzumab has been reported to induce a neutralizing antibody response resulting in reduce efficacy of Trastuzumab. This kit allows researchers to qualitatively monitor the presence of anti-Trastuzumab antibodies in biological matrices.
PRINCIPLE OF THE ASSAY
This immunogenicity assay employs the bridging ELISA technique. Capture antibody is precoated onto a 96 well microplate. Quality control and test samples are pipetted into the appropriate wells. Anti- Trastuzumab present in biological matrices is bound by the immobilized capture antibody. After washing away any unbound substances, secondary antibody is added to the wells and after a final wash a detection reagent is added. The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development.
The color development is proportional to the amount of anti-Trastuzumab present in test samples. Three levels of QC samples give a qualitative reference signal which can be used to determine the level of anti-Trastuzumab antibody in the unknown samples. The color development is stopped and the intensity of the color is measured.
Product Properties
Detection method: Peroxidase / OD450
Storage and stability: Stable at -20°C for 1 year
Safety Warnings and Precautions: Research Use Only. Follow instructions.
Precision : Intra-assay coefficient of variation (CV) <10%. Inter-assay CV <10%.
Detection limit : 31.3ng/ml
Each kit includes:
- Coated microtiter plate, 96 wells
- QC samples - 4x50ul
- 10X wash buffer - 25ml
- Assay buffer - 50ml
- 1000X secondary antibody - 17ul
- 1000X detection reagent - 17ul
- TMB - 12ml
- TMB stop solution - 12ml
- Plate sealers - 3
| Is Featured? | No |
|---|
Write Your Own Review